MYCN and Metabolic Reprogramming in Neuroblastoma.
MYCN and Metabolic Reprogramming in Neuroblastoma.
复制标题
MYCN与神经母细胞瘤中的代谢重编程
DOI：
10.3390/cancers14174113
复制
发表时间：
2022-08-25
期刊：
影响因子：
5.2
通讯作者：
Ding, Han-Fei
中科院分区：
文献类型：
--
作者：
Bansal, Mohit;Gupta, Anamika;Ding, Han-Fei
代谢重编程在癌症的发生和发展中起着核心作用，包括高危神经母细胞瘤，一种致命的儿童交感神经系统恶性肿瘤。这种细胞代谢的重新布线增加了生物质生产的燃料和构建块的制造，这对于维持神经母细胞瘤细胞的生长和增殖至关重要。然而，重新布线也使神经母细胞瘤细胞在代谢方面与正常交感神经元不同，从而提供了新的治疗机会。本文就近年来神经母细胞瘤代谢重编程及其分子机制的研究进展作一综述。神经母细胞瘤是一种儿童癌症，约占儿童癌症死亡人数的15%。基因组MYCN扩增导致的MYCN异常激活是高风险神经母细胞瘤的主要驱动因素，尽管目前有最好的治疗方法，但其总生存率仍低于50%。代谢重编程是MYCN驱动的生长促进程序的一个组成部分，MYCN通过增加营养物质的摄取和分解代谢、大分子的生物合成和能量的产生来促进细胞的生长和增殖。这种重编程过程也会产生代谢脆弱性，可以用于治疗。在这篇综述中，我们介绍了我们目前对神经母细胞瘤代谢重编程的理解，重点是转录调控是驱动重编程过程的关键机制。我们还强调了一些需要探索的重要领域，以成功开发基于代谢的治疗高危神经母细胞瘤的方法。
Metabolic reprogramming has a central role in the initiation and progression of cancer, including high-risk neuroblastoma, a deadly childhood malignant tumor of the sympathetic nervous system. This rewiring of cellular metabolism increases the manufacture of fuel and building blocks for biomass production, which is essential to sustain the growth and proliferation of neuroblastoma cells. However, the rewiring also makes neuroblastoma cells metabolically distinct from normal sympathetic neurons, thereby offering new therapeutic opportunities. In this review, we summarize the recent progress in the study of neuroblastoma metabolic reprogramming and underlying molecular mechanisms. Neuroblastoma is a pediatric cancer responsible for approximately 15% of all childhood cancer deaths. Aberrant MYCN activation, as a result of genomic MYCN amplification, is a major driver of high-risk neuroblastoma, which has an overall survival rate of less than 50%, despite the best treatments currently available. Metabolic reprogramming is an integral part of the growth-promoting program driven by MYCN, which fuels cell growth and proliferation by increasing the uptake and catabolism of nutrients, biosynthesis of macromolecules, and production of energy. This reprogramming process also generates metabolic vulnerabilities that can be exploited for therapy. In this review, we present our current understanding of metabolic reprogramming in neuroblastoma, focusing on transcriptional regulation as a key mechanism in driving the reprogramming process. We also highlight some important areas that need to be explored for the successful development of metabolism-based therapy against high-risk neuroblastoma.
登录
查看更多内容
影响因子：
50.3
作者：
Carroll PA;Diolaiti D;McFerrin L;Gu H;Djukovic D;Du J;Cheng PF;Anderson S;Ulrich M;Hurley JB;Raftery D;Ayer DE;Eisenman RN
通讯作者：
Eisenman RN
影响因子：
6
作者：
Alam, Goleeta;Cui, Hongjuan;Ding, Han-Fei
通讯作者：
Ding, Han-Fei
影响因子：
22.7
作者：
Alborzinia, Hamed;Florez, Andres F.;Kreth, Sina;Brueckner, Lena M.;Yildiz, Umut;Gartlgruber, Moritz;Odoni, Dorett, I;Poschet, Gernot;Garbowicz, Karolina;Shao, Chunxuan;Klein, Corinna;Meier, Jasmin;Zeisberger, Petra;Nadler-Holly, Michal;Ziehm, Matthias;Paul, Franziska;Burhenne, Juergen;Bell, Emma;Shaikhkarami, Marjan;Wuerth, Roberto;Stainczyk, Sabine A.;Wecht, Elisa M.;Kreth, Jochen;Buettner, Michael;Ishaque, Naveed;Schlesner, Matthias;Nicke, Barbara;Stresemann, Carlo;Llamazares-Prada, Maria;Reiling, Jan H.;Fischer, Matthias;Amit, Ido;Selbach, Matthias;Herrmann, Carl;Woelfl, Stefan;Henrich, Kai-Oliver;Hoefer, Thomas;Trumpp, Andreas;Westermann, Frank
通讯作者：
Westermann, Frank
影响因子：
56.9
作者：
BRODEUR, GM;SEEGER, RC;BISHOP, JM
通讯作者：
BISHOP, JM
DOI：
10.1016/j.biocel.2007.01.020
发表时间：
2008-01-01
影响因子：
4
作者：
Ameri, Kurosh;Harris, Adrian L.
通讯作者：
Harris, Adrian L.